Iperboreal Pharma

Name

Iperboreal Pharma

Legal name

Iperboreal Pharma Srl

Website

https://iperboreal.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Peritoneal Dialysis Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAHAKAB

Peritoneal Dialysis (PD) Systems & Supplies

Healthcare & Life Sciences/Medical Devices & Diagnostics/Renal & Dialysis Devices

SECONDARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Peritoneal dialysis solutions
• Renal replacement therapy
• Osmo-metabolic formulations
• Medical device development
• Preclinical CRO services

Headquarters

HQ city

Pescara

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Licensing agreements: Establishing licensing agreements with multinational pharmaceutical and biomedical instrumentation companies for developed products.
2. Co-development partnerships: Co-development arrangements with partners where the company provides therapeutic platform and receives development milestones and royalties.
3. Technology transfer: Transfer of intellectual property and technology to larger companies for commercialization.
4. Preclinical CRO services: Contract research organization services offering preclinical expertise to take drugs or medical devices from concept to market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Iperboreal Pharma researches and develops pharmaceutical products and medical devices for peritoneal dialysis (PD), with a focus on glucose-sparing and osmo-metabolic formulations. Its portfolio includes glucose-based and xylitol-based hypertonic dialysis solutions (GlucoThera family, XyloThera, PolyCore) targeting end-stage renal disease and refractory congestive heart failure, plus the LeanPD medical device that automates dialysate administration with real-time intraperitoneal pressure monitoring. The company brings products up to the precompetitive industrial development phase and then establishes licensing, co-development, or technology transfer agreements with multinational pharmaceutical and biomedical instrumentation companies, while also offering preclinical CRO services.

Product overview

Iperboreal Pharma develops a portfolio of pharmaceutical products and medical devices for peritoneal dialysis. The product portfolio includes six hypertonic dialysis solutions (GlucoThera, GlucoThera Low Sodium, GlucoThera Plus, XyloThera, and PolyCore) and one medical device (LeanPD). The solutions employ a glucose-sparing and osmo-metabolic approach, using active osmotic agents like carnitine and xylitol to reduce glucose content while maintaining biocompatibility. The LeanPD device integrates with the therapeutic platform by providing automated delivery with intraperitoneal pressure monitoring. The company targets two main therapeutic areas: End-Stage Renal Disease (ESRD) requiring peritoneal dialysis, and Refractory Congestive Heart Failure.

Differentiator

Problem solved

Functional benefit

Brands

• LeanPD: Innovative medical device for the automated administration of hypertonic solutions into the peritoneal cavity of patients undergoing renal replacement therapy.
• GlucoThera
• GlucoThera Low Sodium
• GlucoThera Plus
• XyloThera
• PolyCore
• XyloCore

Products and services

• LeanPD Innovative medical device for the automated administration of hypertonic solutions into the peritoneal cavity of patients undergoing renal replacement therapy (peritoneal dialysis). Its distinguishing capability is real-time monitoring of intraperitoneal pressure throughout the dialysis procedure to prevent overfilling or negative-pressure emptying complications.
• GlucoThera Glucose-based peritoneal dialysis solutions formulated for Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD), serving as the baseline PD formulation in the company's portfolio for end-stage renal disease patients.
• GlucoThera Low Sodium Low-sodium glucose-based peritoneal dialysis solutions for CAPD and APD, designed for renal patients requiring reduced sodium exposure.
• GlucoThera Plus Glucose-based peritoneal dialysis solutions targeted at patients with carnitine deficiency, formulated for CAPD and APD.
• XyloThera (XyloCore) Osmo-metabolic-based peritoneal dialysis solutions for CAPD and APD containing xylitol as an active osmotic agent, allowing significant reduction in glucose content while maintaining filtration efficacy and improving glucose and lipid homeostasis; in Phase III development for end-stage kidney disease and registered under the trial product name XyloCore (EudraCT 2019-004183-21).
• PolyCore Osmo-metabolic and colloidal-based ultrafiltration solution for CAPD designed for peritoneal ultrafiltration therapy in refractory congestive heart failure, containing bioactive agents that preserve the peritoneum and exert favorable metabolic effects; in Phase II development (EudraCT 2019-004670-25).
• Preclinical Contract Research Organization (CRO) Services Contract research organization services providing preclinical expertise to pharmaceutical, biotech, and medical device clients, covering identification of new therapeutic targets, preclinical pharmacology, engineering, and prototyping to advance assets from concept to market.

Quantifiable outcome

• Significant reduction in glucose content while maintaining satisfactory filtration efficacy across the peritoneum
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves4 records

Expansion highlights6 records

Regional players

• Diaverum: European-headquartered dialysis services provider operating hundreds of clinics across the continent. Relevant regional player in the same ESRD patient population Iperboreal targets, potential clinical and commercial partner in Europe.

Broad incumbents

• DaVita: Leading US dialysis services operator expanding peritoneal dialysis and home therapies. Major potential licensing partner and end-customer channel for Iperboreal's PD solutions, given its scale of PD patient management.
• Nipro Corporation: Japanese medical device and pharmaceutical company with a significant PD solutions business in Asia. Comparable multinational PD solution manufacturer and natural licensing/acquisition counterpart for Iperboreal's glucose-sparing formulations.
• Fresenius Medical Care: World's largest dialysis products and services company with PD solutions (Balance, glucose-based) and home dialysis devices. Direct incumbent competitor with vertically integrated PD franchise and global nephrology relationships.
• Asahi Kasei Medical: Japanese dialysis products manufacturer with global PD and hemodialysis consumables footprint. Comparable incumbent in PD solutions and dialysis membranes, potential licensing partner for Asian market expansion.
• Baxter International: Global leader in PD solutions with established brands (Dianeal, Extraneal, Nutrineal) and integrated home dialysis portfolio. Most directly comparable incumbent whose PD franchise Iperboreal's glucose-sparing formulations would compete against or be licensed into.
• Terumo Corporation: Japanese medical device and pharmaceutical company with established renal/pd business (Terumo Blood and Cell Technologies and PD-related consumables). Comparable as a diversified multinational with PD franchise and licensing/partnering track record.

Emerging players

• Outset Medical: Public US company behind the Tablo hemodialysis system, targeting home and acute dialysis with a connected device platform. Comparable as an innovation-driven dialysis device company pursuing differentiated, patient-friendly renal replacement therapies.
• Mozarc Medical: Joint venture between Medtronic and BD focused on renal care solutions, including home dialysis technologies. Emerging player comparable in scale and ambition to Iperboreal's PD-focused innovation strategy.
• Physidia: French medical device company specializing in automated peritoneal dialysis cyclers (e.g., Physidia S3 system) for home use. Closest direct peer in profile: small European PD-focused device innovator pursuing improved home PD outcomes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/iperborealpharma
• LinkedInlinkedin.com/company/iperboreal-pharma-s-r-l-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iperboreal Pharma